Abstract
AIMS: High levels of plasma triglycerides (TG) are a risk factor for cardiovascular diseases often associated with anomalies in other lipids or lipoproteins. However, results from randomized trials, suggesting that low high density lipoprotein cholesterol (HDLc) might not cause cardiovascular disease, as originally thought, have generated renewed interest in increased concentrations of TG. The objective has been to determine the prevalence and factors associated with hypertrigliceridemia (HTG) and with low HDLc. Methods: Patients, included in the HTG Registry of the Spanish Association of Atherosclerosis, have been analyzed and anthropometric as well as metabolic data have been collected from them. Results: 1349 patients have been evaluated. Low HDLc has been found in 60.86% (821). Factors significantly associated with low HDLc and HTG were the female sex, being overweight with an increase in the body mass index, using tobacco, diabetes mellitus, low-alcohol consumption and a low exercise rate. Among them, two types of association may be identified with anthropometric variables (especially in men) and metabolic variables (diabetes mellitus and metabolic syndrome). No significant differences have been found insofar as the prevalence of cardiovascular illness between both groups. Conclusions: HTG - low HDLc association is very frequent and it is related to overweight-obesity and other metabolic disorders such as diabetes mellitus with or without metabolic syndrome. In addition, these findings underscore the intricate relationship between HDLc, TG, and glucose metabolism that need to be studied simultaneously. In this context, TG lowering treatment is suggested to be more strongly recommended to address the residual risk of atherosclerotic cardiovascular disease.
Keywords: Hypertriglyceridemia, low-HDLc, cardiovascular risk, metabolic syndrome, obesity.
Current Pharmaceutical Design
Title:Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Volume: 22 Issue: 3
Author(s): Jesús Millán-Núñez, Teresa Mantilla-Morató, Rocio Toro, Joaquin J. Millán-Pérez, Alipio Mangas- Rojas and members of the Scientific Committee of the Hypertriglyceridemia Registry of the Spanish Society of Arteriosclerosis (SEA) (†)
Affiliation:
Keywords: Hypertriglyceridemia, low-HDLc, cardiovascular risk, metabolic syndrome, obesity.
Abstract: AIMS: High levels of plasma triglycerides (TG) are a risk factor for cardiovascular diseases often associated with anomalies in other lipids or lipoproteins. However, results from randomized trials, suggesting that low high density lipoprotein cholesterol (HDLc) might not cause cardiovascular disease, as originally thought, have generated renewed interest in increased concentrations of TG. The objective has been to determine the prevalence and factors associated with hypertrigliceridemia (HTG) and with low HDLc. Methods: Patients, included in the HTG Registry of the Spanish Association of Atherosclerosis, have been analyzed and anthropometric as well as metabolic data have been collected from them. Results: 1349 patients have been evaluated. Low HDLc has been found in 60.86% (821). Factors significantly associated with low HDLc and HTG were the female sex, being overweight with an increase in the body mass index, using tobacco, diabetes mellitus, low-alcohol consumption and a low exercise rate. Among them, two types of association may be identified with anthropometric variables (especially in men) and metabolic variables (diabetes mellitus and metabolic syndrome). No significant differences have been found insofar as the prevalence of cardiovascular illness between both groups. Conclusions: HTG - low HDLc association is very frequent and it is related to overweight-obesity and other metabolic disorders such as diabetes mellitus with or without metabolic syndrome. In addition, these findings underscore the intricate relationship between HDLc, TG, and glucose metabolism that need to be studied simultaneously. In this context, TG lowering treatment is suggested to be more strongly recommended to address the residual risk of atherosclerotic cardiovascular disease.
Export Options
About this article
Cite this article as:
Millán-Núñez Jesús, Mantilla-Morató Teresa, Toro Rocio, Millán-Pérez J. Joaquin, Mangas- Rojas Alipio and members of the Scientific Committee of the Hypertriglyceridemia Registry of the Spanish Society of Arteriosclerosis (SEA) (†) , Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc, Current Pharmaceutical Design 2016; 22 (3) . https://dx.doi.org/10.2174/1381612822666151112150831
DOI https://dx.doi.org/10.2174/1381612822666151112150831 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Clinical Consequences and Novel Therapy of Hyperphosphatemia: Lanthanum Carbonate for Dialysis Patients
Recent Patents on Cardiovascular Drug Discovery Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Some clinical applications of the electrochemical biosensors
Mini-Reviews in Medicinal Chemistry Graphical Abstracts
Current Drug Delivery Assessment of the Aggregation Propensity of the β -amyloid Peptide During the Synthesis and when Free in Solution
Protein & Peptide Letters Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Application of Aptamer-based Hybrid Molecules in Early Diagnosis and Treatment of Diabetes Mellitus: From the Concepts Towards the Future
Current Diabetes Reviews Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Retinal Neurodegeneration in the Course of Diabetes-Pathogenesis and Clinical Perspective
Current Neuropharmacology Editorial: Oxidative Stress in Pathophysiological Conditions
Current Vascular Pharmacology The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents A Study of Prescription Pattern and Compliance of Anti-hypertensives with the Treatment Guidelines in Aseer Region; Saudi Arabia
Current Drug Therapy Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Therapeutic Angiogenesis for Peripheral Artery Diseases by Autologous Bone Marrow Cell Transplantation
Current Pharmaceutical Design Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Current Pharmaceutical Design